home.aspx
 
. https://biotechnology.report/Resources/Whitepapers/58a2f475-4c81-472f-87c7-050d6375de1e_Trinity_Reimbursement_Challenges-6.10.19-1.pdf
whitepaper
SHARESHARESHARE
EXPLORING THE TRUTH OF REIMBURSEMENT CHALLENGES FOR CELL AND GENE THERAPIES.
Trinity has worked with over a third of companies with cell and gene therapies (CGTs) on market or in Phase 3 clinical trials. Our work has supported business development, launch planning, evidence generation (HEOR, etc.), market access, pricing, and other critical commercial activities to support the development and launch of these therapies.1 As such, we have seen CGTs morph from a small niche into possibly the most exciting market in pharma. DOWNLOAD